EPISODE · Jul 21, 2023 · 53 MIN
Is the FDA Too Cautious?
from Open to Debate · host Open to Debate
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious? Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest Emmy award-winning journalist John Donvan moderates Learn more about your ad choices. Visit podcastchoices.com/adchoices
What this episode covers
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious? Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest Emmy award-winning journalist John Donvan moderates Learn more about your ad choices. Visit podcastchoices.com/adchoices
NOW PLAYING
Is the FDA Too Cautious?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m